Tracy George, MD, The University of Utah, Salt Lake City, UT, talks on areas of unmet need for the diagnosis, classification, and treatment of mastocytosis, including optimizing therapeutic approaches in patients with co-existing hematological malignancies often seen in systemic mastocytosis. In indolent mastocytosis, Prof. George highlights the benefit of avapritinib in patients with KIT mutations and touches on the pediatric population who also represent an area of unmet need. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.